The effect depends on a subgroup characteristic, i.e. "tumor histology": For patients with non-epithelioid mesothelioma, there is an indication of considerable added benefit compared to platinum ...

Nivolumab + ipilimumab: Added benefit in pleural mesothelioma with non-epithelioid tumour histology For the first time, a pure antibody combination is approved as first-line therapy for ...

Upstaging at the time of surgical resection is unfortunately a common occurrence in up to 70%-80% of patients with clinical stage I or II and 23% with clinical stage III malignant pleural mesothelioma ...

Malignant pleural effusion (PE) is defined by the presence of malignant cells in pleural fluid or biopsy. The accurate evaluation of PE became more important for tumor staging in the seventh edition ...